- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05.03. | XOMA AB: Further Development of the CLAS System | 1 | Cision News | ||
| 11.02. | XOMA AB: Xoma receives water from a company in the steel industry in Sweden for evaluation | 2 | Cision News | ||
| XOMA CORPORATION PREF Aktie jetzt für 0€ handeln | |||||
| 05.02. | XOMA AB: Xoma initiates a test project with a mine in northern Sweden for process water purification | 3 | Cision News | ||
| 03.02. | Forecasting The Future: 5 Analyst Projections For XOMA Royalty | 3 | Benzinga.com | ||
| 17.01. | XOMA AB: Xoma collaborates with Professor Christiane Funk at Umeå University on the FLOW (Filtration of Liquids and Organic Waste) technology | 1 | Cision News | ||
| 17.01. | XOMA AB: Xoma launches a new website and updated visual identity | 2 | Cision News | ||
| 10.01. | Chief Investment Officer von Xoma Royalty erwirbt Aktien im Wert von 13.974 US-Dollar | 2 | Investing.com Deutsch | ||
| 03.01. | Dividendenbekanntmachungen (03.01.2025) | 15.616 | wallstreetONLINE (Dividenden) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AGRICULTURAL BANK OF CHINA LTD ADR US00850M1027 0,4001 USD 0,3897 EUR AMERICAN EXPRESS COMPANY US0258161092 0,7 USD 0,6818 EUR AUTO... ► Artikel lesen | |
| 02.01. | XOMA Preferred Shares Series A goes ex dividend tomorrow | 2 | Seeking Alpha | ||
| 19.12.24 | XOMA Corp - 8.375% DP PFD B declares $0.5234 dividend | 1 | Seeking Alpha | ||
| 19.12.24 | XOMA Preferred Shares Series A declares $0.5391 dividend | 2 | Seeking Alpha | ||
| 19.12.24 | XOMA Royalty Corporation: XOMA Royalty Declares Quarterly Preferred Stock Dividends | 1 | GlobeNewswire (USA) | ||
| 10.12.24 | XOMA AB: First Delivery of Process Water from a Swedish Industry | 1 | Cision News | ||
| 06.12.24 | XOMA AB: Xoma engages Kalqyl and FairValue to strengthen its investor communications | 2 | Cision News | ||
| 03.12.24 | A Glimpse Into The Expert Outlook On XOMA Royalty Through 4 Analysts | 2 | Benzinga.com | ||
| 02.12.24 | XOMA Royalty Owns Economic Interest In Seralutinib With Pulmokine Purchase; Stock Up | 1 | RTTNews | ||
| 02.12.24 | XOMA Royalty Corp - 8-K, Current Report | - | SEC Filings | ||
| 02.12.24 | XOMA Corporation: XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio | 129 | GlobeNewswire (Europe) | Seralutinib becomes XOMA Royalty's seventh Phase 3 royalty asset, further building the late-stage pipeline beyond its six current commercial royalty assets Seralutinib is being developed and co-commercialized... ► Artikel lesen | |
| 19.11.24 | Spotlight Stock Market: Market Notice 237/24 - Xoma AB will be listed on Spotlight Stock Market on November 22, 2024 | 3 | Cision News | ||
| 07.11.24 | XOMA Corporation: XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities | 132 | GlobeNewswire (Europe) | Zevra's MIPLYFFA (arimoclomol) received FDA approval and became the sixth commercial asset in XOMA Royalty's portfolio XOMA Royalty acquired a 50 percent economic interest in TWIST Bioscience's portfolio... ► Artikel lesen |
Seite:
1 2 Weiter >>
40 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TEMPUS AI | 45,620 | 0,00 % | Cathie Wood's ARK buys Tempus AI stock, sells Block Inc | ||
| ADMA BIOLOGICS | 18,280 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update | FY 2024 Total Revenue of $426.5 Million, a 65% YoY Increase FY 2024 GAAP Net Income of $197.7 Million, Including an $84.3 Million Valuation Allowance Tax Benefit FY 2024 Adjusted EBITDA(1)... ► Artikel lesen | |
| BIONTECH | 91,90 | +1,77 % | BioNTech-Konkurrent Moderna mit Kurssprung - das ist der Grund | In den vergangenen Wochen und Monaten sorgte eine negative News nach der anderen bei Moderna für lange Gesichter unter den Anlegern. Die Aktie fiel von einem Tief zum nächsten. Doch am Mittwoch hat... ► Artikel lesen | |
| QIAGEN | 36,170 | -0,08 % | Biotech Report: Evotec und Qiagen rutschen ab | (shareribs.com) Frankfurt / New York 07.03.2025 - Biotech-Aktien tendierten im deutschen Handel überwiegend schwächer. Evotec und Qiagen gaben nach. An der Wall Street konnte der Sektor nicht zulegen.... ► Artikel lesen | |
| EVOTEC | 6,185 | -0,32 % | Evotec: Zahlen-Schock in Kürze? | Die Evotec-Aktie hatte trotz einer operativer Erfolgsnews wie einer neuerlichen Meilensteinzahlung von Partner Bristol-Myers einen katastrophalen Start in den Monat März. Verunsicherung schafft unter... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 6,170 | 0,00 % | Jim Cramer on Recursion Pharmaceuticals, Inc. (RXRX): 'We're Going To Have To Hold Off' | ||
| MINERALYS THERAPEUTICS | 13,040 | 0,00 % | Mineralys Therapeutics Aktie: Revolutionärer Fortschritt! | Die Aktie von Mineralys Therapeutics verzeichnete einen beeindruckenden Anstieg auf ein 52-Wochen-Hoch von 15,41 US-Dollar, nachdem das Unternehmen vielversprechende Ergebnisse aus seinen klinischen... ► Artikel lesen | |
| ARVINAS | 9,020 | 0,00 % | Pre-market Movers: 2seventy bio, Sonoma Pharmaceuticals, Tenon Medical, Arvinas, NET Power Inc. | LONDON (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 09.00 A.M. ET).In the Green 2seventy bio, Inc. (TSVT) is up over 76% at $4.93.
Sonoma... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 20,040 | 0,00 % | Evercore ISI launches Summit Therapeutics with Outperform rating | ||
| DOGWOOD THERAPEUTICS | 10,330 | 0,00 % | Dogwood Therapeutics, Inc. Announces Conversion of Existing $19.5M in Debt to Equity, Strengthening Balance Sheet Moving Forward | ATLANTA, March 12, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) ("Dogwood" or the "Company"), a development-stage biopharmaceutical company focused on advancing first-in-class... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 24,910 | 0,00 % | Piper Sandler maintains $51 target on Edgewise Therapeutics stock | ||
| BEAM THERAPEUTICS | 26,870 | 0,00 % | Beam Therapeutics Reprots Positive Initial Phase 1/2 Data For BEAM-302 In AATD | WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) Monday reported positive initial data from its Phase 1/2 study of BEAM-302 for the treatment of alpha-1 antitrypsin deficiency (AATD).AATD... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 50,56 | 0,00 % | SpringWorks Shares Rise More Than 30% in 3 Months: Here's Why | ||
| ARCELLX | 72,74 | 0,00 % | Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights | REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 21,620 | 0,00 % | Structure Therapeutics Inc.: Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D. as Chief Development Officer | SAN FRANCISCO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen |
XOMA CORPORATION PREF gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 23,400 Euro und damit +4,46 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu XOMA CORPORATION PREF finden Sie auf Wallstreet Online.
